( Figure 1 ). HNE was also significantly elevated in CML BM supernatant separated from samples taken before IM treatment (52517162 ng/ml, n ¼ 6) with respect to non-CML controls (21547695 ng/ml, n ¼ 3; P ¼ 0.003). After treatment with IM for longer than 4 weeks, PB HNE levels normalized (5173 ng/ml, n ¼ 13) in parallel with correction of WBC ( Table 2) .
At 12 weeks post-IM, there were no significant differences in HNE levels between those patients in complete cytogenetic remission (CCR) versus cytogenetic non-responders in their PB (61713, n ¼ 4 versus 58710 ng/ml, n ¼ 5) or BM (26497282 versus 18817471 ng/ml; both groups n ¼ 6 with normal WBC), with all CML BM samples not significantly different from non-CML controls.
In CP CML at diagnosis, PB HNE levels were significantly elevated relative to normal controls. Interestingly, we have previously noted an inverse correlation between total WBC and G-CSF protein levels in CML patients in early CP 3 that, based on the current observation, may result in part from degradation of G-CSF by HNE. Yong et al. 6 have shown a correlation between longer survival times and high elastase (ELA2) or proteinase-3 (PR3) gene expression with low CD7 in CML. However, treatment of our cohort of patients with IM resulted in normalization of PB HNE protein and WBC. Further, at 12 weeks post-IM, there were no differences in either PB or BM HNE protein levels between CML patients in CCR and cytogenetic non-responders, or between CML BM samples and non-CML controls. In conclusion, HNE protein is an unsuitable differential target for therapy in IM-treated CP CML. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34 þ selected allogeneic hematopoietic cell transplantation Allogeneic hematopoietic cell transplantation represents an effective and potentially curative therapy for patients with chronic myeloid leukemia (CML). 1 The efforts to decrease the risk of graft-versus-host disease (GVHD) as a major cause of transplant-related mortality by depleting T cells from the graft resulted in an increased incidence of CML relapse. 2 These observations revealed that donor T cells representing the mediators of GVHD are also capable of inducing therapeutic Po0.005, NS (not significant) with respect to pre-IM treatment. NS (not significant) with respect to normal controls (PB: 6473 ng/ml, non-CML marrow: 21547695 ng/ml).
Letters to the Editor graft-versus-leukemia (GVL) effects. Patients with disease recurrence after transplantation have been treated with donor lymphocyte infusion (DLI), which induced complete remissions in the majority of patients with CML in chronic phase. 3 However, DLI is often associated with significant acute or chronic GVHD. The main challenge is therefore to augment the donor T-cell-mediated antileukemia effects without causing relevant GVHD.
To dissociate the GVL effect from GVHD, much attention has been paid to the identification of well-defined peptides derived from CML-associated antigens that may serve as target structures for T cells. Thus, a human leukocyte antigen (HLA)-A2-restricted proteinase 3-derived peptide which is capable of inducing CMLreactive cytotoxic T cells (CTLs) has been identified and a strong correlation between the presence of proteinase 3 peptidereactive CTLs and clinical responses of CML patients after therapy with interferon-alpha or allogeneic hematopoietic cell transplantation has been reported. 4 Further studies demonstrated the identification of peptides derived from the b3a2 breakpoint region of bcr/abl which bind to different HLA molecules and efficiently elicit CTL responses. 5 Recently, the existence of circulating CD8 þ T cells directed against bcr/abl peptides in CML patients and healthy donors has been documented. 6, 7 Here, we report the case of a 42-year-old female patient who experienced cytogenetic relapse 15 months after having started imatinib mesylate for chronic phase CML. Having identified an HLA-compatible donor, she was scheduled for allogeneic hematopoietic cell transplantation. After informed consent, she was included in a trial investigating the infusion of ex vivoactivated CTL after CD34
þ -selected hematopoietic cell transplantation.
According to protocol, conditioning therapy had been performed with total body irradiation divided into four fractions of 200 cGy at a total dose of 800 cGy (days -8 to -7), 40 mg/m 2 fludarabine i.v. over 5 days (day -6 to -2; total dose 200 mg/m 2 ), thiotepa 2 Â 5 mg/kg on day -6 (total dose 10 mg/kg), antityhmocyte globulin 5 mg/kg over 5 days (days -5 to -1, total dose 25 mg/kg) and cyclosporin A at 1 mg/kg per day from days -9 to -3. CD34
þ -selected granulocyte-colony-stimulating factor-mobilized peripheral blood stem cells from her HLAidentical brother were infused on day 0. No further posttransplant GvHD prophylaxis was administered. Immunomagnetic isolation of monocytes at high purity (490%) from the leukapheresis product of the second day and the generation of mature dendritic cells (DCs) was performed as described previously. 8 According to the HLA class I-type of the CML patient, mature donor DCs were loaded with 20 mg/ml of the HLA-A2-binding bcr/abl-derived peptide SSKALQRPV or the proteinase 3-derived peptide VLQELNVTV as well as with the HLA-B8-binding bcr/abl-derived peptide GFKQSSKAL for 4 h. After washing, peptide-loaded DCs were cocultured with immunomagnetically isolated autologous CD8 þ T cells as described. 9 After three rounds of weekly stimulation, cultures were tested for the presence of peptide-specific CTLs in a 4 h 51 Cr-release assay. As demonstrated in Figure 1 , CTLs efficiently lysed HLA-B8-positive DCs loaded with the peptide GFKQSSKAL, whereas only marginal killing was obtained when unloaded DCs or DCs pulsed with the control peptide VPKLKVCAL representing a natural ligand of HLA-B8 were used as targets. In addition, DCs loaded with the HLA-An0201-restricted peptides SSKALQRPV or VLQELNVTV were not significantly lysed.
The generated T cells containing bcr/abl peptide-specific CTLs were subsequently infused (2.4 Â 10 6 /kg on day 56 and 1.2 Â 10 6 /kg CTL on day 112 after transplantation). The infusion of CTLs was well tolerated without occurrence of acute or chronic GvHD. No infectious complication or severe adverse effect requiring hospitalization was observed throughout the follow-up. After 26 months, the patient is alive in molecular remission as defined by negativity in the bcr/abl realtime-polymerase chain reaction (PCR). Although she became PCR-positive (ratio bcr/abl to abl: 0.002%) on day 650, she achieved molecular remission again without further intervention (Figure 2) .
We cannot yet prove conclusively that the molecular remission was induced by the limited number of peptidereactive CTL rather than by nonspecific allogeneic effector cells. The efficacy of leukemia-reactive CTLs had been previously described even in advanced phase of CML. 10 The lack of clinically relevant acute and chronic GvHD and the achievement of molecular remission support our current approach to schedule the infusion of CTLs as an early intervention. The risk of molecular relapse after CD34 þ -selected peripheral blood stem cell transplantation has been shown to be as high as 88%, which provides a further argument for the potential efficacy of our approach.
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Taken together, we demonstrated that the adoptive transfer of in vitro-generated bcr-abl peptide-reactive CTLs after CD34 þ -selected allogeneic hematopoietic cell transplantation resulted in molecular remission of CML without causing clinically relevant acute and chronic GvHD. These results provide evidence that the infusion of CTL reactive against leukemiaassociated antigens may represent an attractive strategy to dissociate the GVL effect from GVHD. Furthermore, the In vitro generation of bcr/abl peptide-specific cytotoxic T lymphocytes. After three rounds of stimulation with peptide-pulsed DCs, activated CD8 þ T cells from the donor were cocultured with 5 Â 10 3 51
Cr-labeled DCs loaded with 50 mg/ml of the HLA-An0201-restricted bcr/abl-derived peptide SSKALQRPV or the proteinase 3-derived peptide VLQELNVTV, the HLA-Bn0801-restricted bcr/ablderived peptide GFKQSSKAL or the control peptide VPKLKVCAL at different E:T ratios Letters to the Editor potential reduction of morbidity and mortality of this treatment modality may be an important step towards a reappraisal of allogeneic transplantation as a curative therapy in patients with an unsatisfactory response to primary treatment with tyrosine kinase inhibitors or those developing secondary resistance owing to mutations in the tyrosine kinase domain. In addition, the infusion of T-cells reactive against tumor-associated antigens after CD34
þ -selected transplantation may also be warranted in other hematological malignancies in which potential CTL targets have been identified. However, future studies in larger cohorts will be necessary to confirm the promising results observed so far.
Resistance to imatinib in the treatment of chronic myelogenous leukemia (CML) may occur due to amplification of the Bcr-Abl gene, but more frequently by point mutations causing substitutions of critical amino-acid residues in the Abl kinase domain. 1 More than 40 different mutations have been described so far.
2 They confer resistance due to amino-acid substitutions, which impair drug binding without influencing ATP binding. 
